The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based immunoassay (ChLIA) test ...

Revvity, Inc. RVTY announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based ...

The ABBOTT PRISM System is an automated immunoassay analyzer designed to perform Chemiluminescent immunoassay (ChLIA) technology. The ABBOTT PRISM performs batch/continuous access and STAT ...

Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation ...

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis ...

These chemiluminescent, no-wash assays are ideally ... advantageously with conventional enzyme-linked immunosorbent assay (ELISA). ELISA is the most widely used detection platform for the ...

The global immunoassay market size is estimated to grow by USD 9.4 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 4.6% during the forecast period. The ...

Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA ...